BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.
Read More…
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Phone949-361-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$46.15 million
Profitability
Miscellaneous
Employees190
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
BIOLASE (NASDAQ:BIOL) Frequently Asked Questions
What is BIOLASE's stock symbol?
BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."
When did BIOLASE's stock split? How did BIOLASE's stock split work?
BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.
How were BIOLASE's earnings last quarter?
BIOLASE Inc (NASDAQ:BIOL) posted its quarterly earnings data on Thursday, August, 8th. The medical technology company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.03. The medical technology company earned $8.65 million during the quarter, compared to analysts' expectations of $12.76 million. BIOLASE had a negative return on equity of 159.26% and a negative net margin of 47.46%. View BIOLASE's Earnings History.
When is BIOLASE's next earnings date?
What price target have analysts set for BIOL?
4 brokerages have issued 12-month price objectives for BIOLASE's stock. Their predictions range from $2.00 to $3.00. On average, they anticipate BIOLASE's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 133.6% from the stock's current price. View Analyst Price Targets for BIOLASE.
What is the consensus analysts' recommendation for BIOLASE?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.
Has BIOLASE been receiving favorable news coverage?
Headlines about BIOL stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIOLASE earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the medical technology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for BIOLASE.
Who are some of BIOLASE's key competitors?
What other stocks do shareholders of BIOLASE own?
Who are BIOLASE's key executives?
BIOLASE's management team includes the folowing people:
- Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
- Mr. John R. Beaver, Exec. VP & CFO (Age 58)
- Mr. Richard R. Whipp, VP of Operations (Age 67)
- Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
- Mr. Daniel Merkin, National Sales Director (Age 46)
Who are BIOLASE's major shareholders?
BIOLASE's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (24.29%), Vanguard Group Inc. (4.50%) and BlackRock Inc. (1.40%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE.
Which major investors are selling BIOLASE stock?
Which major investors are buying BIOLASE stock?
BIOL stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE.
How do I buy shares of BIOLASE?
Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BIOLASE's stock price today?
One share of BIOL stock can currently be purchased for approximately $1.07.
How big of a company is BIOLASE?
BIOLASE has a market capitalization of $23.44 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.
What is BIOLASE's official website?
How can I contact BIOLASE?
BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]
MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
